Good morning, ladies and gentlemen.
I would especially like to welcome our medical professionals today. We have people from the Canadian Medical Association, the Federation of Medical Regulatory Authorities of Canada, the Ontario Ministry of Community Safety and Correctional Services, and the Canadian Men in Nursing Group.
We welcome you. We're very happy you could make it to our committee this morning. We will have your presentations very shortly.
Before we do that, I would like to remind members that we should leave approximately 15 minutes at the end of the meeting to deal with the motion from Ms. Wasylycia-Leis. We also have a budget to consider for future witnesses. Some of our witnesses are coming from quite far away, so we really have to deal with that today.
Pursuant to Standing Order 108(2), I would like to welcome you all to the fifth meeting on post-market surveillance of pharmaceutical products, prescription and non-prescription.
I would like to remind the witnesses that you have 10 minutes per organization to make your presentations. Keep your eyes on me, because I will cut you off and I don't like to do that. I just want to make sure everybody gets a chance to speak, and that all members around the table get a chance to ask you questions. We will hear all your presentations before proceeding to questions.
Let us begin with Dr. John Haggie, chair of the Canadian Medical Association.